PTPRO promoter methylation is predictive of poorer outcome for HER2-positive breast cancer: indication for personalized therapy

Journal of Translational Medicine

Hao Zhang²  Yu-Ping Chen¹  Xiao-Xuan Zheng²  Xiao-Fang Zou²  Zong-Tai Li²  Zhou Li²  Chen Ke²  Fei-Fei Li²  Yi-Teng Huang² 

[1] Department of Thoracic Surgery, Affiliated Cancer Hospital of Shantou University Medical College, Shantou 515041, China;Cancer Research Center, Shantou University Medical College, Shantou 515041, China

关键词: Prognosis;    HER2;    Methylation;    PTPRO;    Breast cancer;   

Others  :  1149087
DOI  :  10.1186/1479-5876-11-245

 received in 2013-07-01, accepted in 2013-09-25,  发布年份 2013

【 摘 要 】

Background

Protein Tyrosine Phosphatase Receptor-type O (PTPRO) has recently been in the spotlight as a tumor suppressor, whose encoding gene is frequently methylated in cancers. We examined the methylation status of the PTPRO gene promoter in breast cancer and evaluated the correlation between PTPRO promoter methylation and both clinicopathological parameters and prognosis of breast cancer patients.

Methods

Two hundred twenty-one formalin-fixed, paraffin-embedded (FFPE) tumor tissues, 20 FFPE normal adjacent tissues and 24 matched plasma samples, collected from primary breast cancer patients, were assessed for PTPRO gene promoter methylation using methylation-specific PCR. Associations of promoter methylation with clinicopathological parameters were evaluated. Kaplan-Meier survival analysis and Cox proportional hazards models were used to estimate the effect on survival.

Results

175 samples gave identifiable PCR products, of which 130 cases (74.3%) had PTPRO gene promoter methylation. PTPRO methylation correlated with higher histological grade (P = 0.028), but not other clinical parameters. Multivariate analysis indicated that overall survival (OS) was significantly poorer in HER2-positive, but not ER-positive patients with methylated-PTPRO. Methylated-PTPRO was detectable in matched plasma samples and only observed in plasma from patients whose corresponding primary tumors were also methylated.

Conclusions

PTPRO methylation is a common event in the primary breast cancer and can be reliably detected in peripheral blood samples. PTPRO methylation is associated with poor survival only in HER2-positive patients, suggesting use of PTPRO methylation as a prognostic factor for breast cancer and for optimizing individualized therapy for HER2-positive patients.

【 授权许可】

   
2013 Huang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Jemal A, et al.: Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
• [2]Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 2012, 490(7418):61-70.
• [3]Cosimo SD, et al.: Management of breast cancer with targeted agents: importance of heterogenicity. Nat Rev Clin Oncol 2010, 7(3):139-147.
• [4]Curtis C, et al.: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486(7403):346-352.
• [5]Van ’t Veer LJ, et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415(6871):530-536.
• [6]Peppercorn J, Perou CM, Carey LA: Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest 2008, 26(1):1-10.
• [7]Perou CM, et al.: Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752.
• [8]Musgrove EA, Sutherland RL: Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009, 9(9):631-643.
• [9]Hudis CA: Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med 2007, 357(1):39-51.
• [10]Muthuswamy SK: Trastuzumab resistance: all roads lead to SRC. Nat Med 2011, 17(4):416-418.
• [11]Seidman A, et al.: Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002, 20(5):1215-1221.
• [12]Wharram BL, et al.: Altered podocyte structure in GLEPP1 (Ptpro)-deficient mice associated with hypertension and low glomerular filtration rate. J Clin Invest 2000, 106(10):1281-1290.
• [13]Aguiar RC, et al.: PTPROt: an alternatively spliced and developmentally regulated B-lymphoid phosphatase that promotes G0/G1 arrest. Blood 1999, 94(7):2403-2413.
• [14]Motiwala T, et al.: Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomas. Oncogene 2003, 22(41):6319-6331.
• [15]You YJ, et al.: Aberrant methylation of the PTPRO gene in peripheral blood as a potential biomarker in esophageal squamous cell carcinoma patients. Cancer Lett 2012, 315(2):138-144.
• [16]Ramaswamy B, et al.: Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivity. Mol Endocrinol 2009, 23(2):176-187.
• [17]Motiwala T, et al.: Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer. Proc Natl Acad Sci U S A 2004, 101(38):13844-13849.
• [18]Mori Y, et al.: Identification of genes uniquely involved in frequent microsatellite instability colon carcinogenesis by expression profiling combined with epigenetic scanning. Cancer Res 2004, 64(7):2434-2438.
• [19]Motiwala T, et al.: Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia. Clin Cancer Res 2007, 13(11):3174-3181.
• [20]Yu M, et al.: Expression profiling during mammary epithelial cell 3D morphogenesis identifies PTPRO as a novel regulator of morphogenesis and ErbB2 mediated transformation. Mol Cell Biol 2012, 32(19):3913-3924.
• [21]Sebova K, et al.: RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer. Cancer Biomark 2011, 10(1):13-26.
• [22]Shetty PJ, et al.: Regulation of IGF2 transcript and protein expression by altered methylation in breast cancer. J Cancer Res Clin Oncol 2011, 137(2):339-345.
• [23]Harbeck N, et al.: Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients. J Clin Oncol 2008, 26(31):5036-5042.
• [24]Melnikov AA, et al.: Array-based multiplex analysis of DNA methylation in breast cancer tissues. J Mol Diagn 2008, 10(1):93-101.
• [25]Sunami E, et al.: Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors. Breast Cancer Res 2008, 10(3):R46. BioMed Central Full Text
• [26]Son KS, et al.: Hypomethylation of the interleukin-10 gene in breast cancer tissues. Breast 2010, 19(6):484-488.
• [27]Baylin SB, Ohm JE: Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006, 6(2):107-116.
• [28]Swift-Scanlan T, et al.: Methylated genes in breast cancer: associations with clinical and histopathological features in a familial breast cancer cohort. Cancer Biol Ther 2011, 11(10):853-865.
• [29]Mehrotra J, et al.: Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung. Clin Cancer Res 2004, 10(9):3104-3109.
• [30]Jacob ST, Motiwala T: Epigenetic regulation of protein tyrosine phosphatases: potential molecular targets for cancer therapy. Cancer Gene Ther 2005, 12(8):665-672.
• [31]Ramezani F, et al.: CpG island methylation profile of estrogen receptor alpha in Iranian females with triple negative or non-triple negative breast cancer: new marker of poor prognosis. Asian Pac J Cancer Prev 2012, 13(2):451-457.